41
Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients
Condition(s):Hemophilia ALast Updated:February 10, 2017Completed
Factor VIII: 880 Clinical Trials, Page 5 of 88
Hide Studies Not Open or Pending
42
Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A
Condition(s):Hemophilia ALast Updated:January 17, 2023Recruiting
43
Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A
Condition(s):Severe Hemophilia ALast Updated:June 9, 2022Completed
44
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Condition(s):Hemophilia ALast Updated:May 24, 2021Completed
45
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc – Von Willebrand Factor – XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
Condition(s):Hemophilia ALast Updated:April 19, 2022Completed
46
A Post Marketing Surveillance Study for ADYNOVATE in South Korea
Condition(s):Hemophilia ALast Updated:December 28, 2021Recruiting
47
Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a “Shuttle”.
Condition(s):Hemophilia ALast Updated:January 6, 2023Active, not recruiting
48
China ADVATE PTP Study
Condition(s):Hemophilia ALast Updated:May 3, 2021Completed
49
A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.
Condition(s):Von Willebrand DiseaseLast Updated:February 15, 2018Completed
50
A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
Condition(s):Hemophilia ALast Updated:January 27, 2023Recruiting